Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hentig

Showing results (1-10 of 57) with videos related to

Pageof 6
Sort By:
Reports (MDPI)|July 29, 2025
A Quantitative and Qualitative Analysis of the Patient and Caregiver's Perspective on Outcomes of Intravenous Administration of Low-Dose Ketamine for C-PTSD, TBI, and Treatment Resistant MDD: A Clinical ExampleLaura Hentig, James Hentig, Jessica M Gill
European Journal of Clinical Pharmacology|March 4, 2021
Repositioning HIV protease inhibitors and nucleos(t)ide RNA polymerase inhibitors for the treatment of SARS-CoV-2 infection and COVID-19Nils von Hentig
Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine|July 6, 2000
Anticompton spectrometer element studiesRiedel, Hentig, Feilitzsch
Drugs of Today (Barcelona, Spain : 1998)|April 5, 2008
Atazanavir/ritonavir: a review of its use in HIV therapyNils von Hentig
Deutsche Medizinische Wochenschrift (1946)|January 24, 2008
[Measurement of the plasma concentration of antiretroviral drugs in HIV therapy]N von Hentig
The Journal of Criminal Law and Criminology, Including the American Journal of Police Science|March 19, 2010
Redhead and outlaw; a study in criminal anthropologyH VON HENTIG
Drugs of Today (Barcelona, Spain : 1998)|April 27, 2007
Lopinavir/ritonavir: appraisal of its use in HIV therapyNils von Hentig
HIV/AIDS (Auckland, N.Z.)|January 6, 2016
Clinical use of cobicistat as a pharmacoenhancer of human immunodeficiency virus therapyNils von Hentig
Drugs of Today (Barcelona, Spain : 1998)|October 17, 2009
A review of current literature on second-generation, sucrose-formulated, full-length recombinant factor VIIIChristoph Konigs, Nils von Hentig
Antimicrobial Agents and Chemotherapy|June 17, 2009
Cytochrome P450 3A inhibition by atazanavir and ritonavir, but not demography or drug formulation, influences saquinavir population pharmacokinetics in human immunodeficiency virus type 1-infected adultsNils von Hentig, Jörn Lötsch
Pageof 6

Showing results (1-10 of 57) with videos related to

Sort By:
Pageof 6
Reports (MDPI)|July 29, 2025
A Quantitative and Qualitative Analysis of the Patient and Caregiver's Perspective on Outcomes of Intravenous Administration of Low-Dose Ketamine for C-PTSD, TBI, and Treatment Resistant MDD: A Clinical ExampleLaura Hentig, James Hentig, Jessica M Gill
European Journal of Clinical Pharmacology|March 4, 2021
Repositioning HIV protease inhibitors and nucleos(t)ide RNA polymerase inhibitors for the treatment of SARS-CoV-2 infection and COVID-19Nils von Hentig
Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine|July 6, 2000
Anticompton spectrometer element studiesRiedel, Hentig, Feilitzsch
Drugs of Today (Barcelona, Spain : 1998)|April 5, 2008
Atazanavir/ritonavir: a review of its use in HIV therapyNils von Hentig
Deutsche Medizinische Wochenschrift (1946)|January 24, 2008
[Measurement of the plasma concentration of antiretroviral drugs in HIV therapy]N von Hentig
The Journal of Criminal Law and Criminology, Including the American Journal of Police Science|March 19, 2010
Redhead and outlaw; a study in criminal anthropologyH VON HENTIG
Drugs of Today (Barcelona, Spain : 1998)|April 27, 2007
Lopinavir/ritonavir: appraisal of its use in HIV therapyNils von Hentig
HIV/AIDS (Auckland, N.Z.)|January 6, 2016
Clinical use of cobicistat as a pharmacoenhancer of human immunodeficiency virus therapyNils von Hentig
Drugs of Today (Barcelona, Spain : 1998)|October 17, 2009
A review of current literature on second-generation, sucrose-formulated, full-length recombinant factor VIIIChristoph Konigs, Nils von Hentig
Antimicrobial Agents and Chemotherapy|June 17, 2009
Cytochrome P450 3A inhibition by atazanavir and ritonavir, but not demography or drug formulation, influences saquinavir population pharmacokinetics in human immunodeficiency virus type 1-infected adultsNils von Hentig, Jörn Lötsch
Pageof 6